[Federal Register Volume 84, Number 26 (Thursday, February 7, 2019)]
[Notices]
[Page 2495]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-01437]
-----------------------------------------------------------------------
DEPARTMENT OF DEFENSE
Office of the Secretary
Uniform Formulary Beneficiary Advisory Panel; Notice of Federal
Advisory Committee Meeting
AGENCY: Under Secretary of Defense for Personnel and Readiness, Uniform
Formulary Beneficiary Advisory Panel, Department of Defense.
ACTION: Notice of federal advisory committee meeting.
-----------------------------------------------------------------------
SUMMARY: The Department of Defense (DoD) is publishing this notice to
announce that the following Federal Advisory Committee meeting of the
Uniform Formulary Beneficiary Advisory Panel will take place.
DATES: Open to the public Wednesday, March 27, 2019 from 9:00 a.m.-
12:00 p.m.
ADDRESSES: The address of the open meeting is the Naval Heritage Center
Theater, 701 Pennsylvania Avenue NW, Washington, DC 20004.
FOR FURTHER INFORMATION CONTACT: Colonel Paul J. Hoerner, USAF, 703-
681-2890 (Voice), None (Facsimile), [email protected] (Email). Mailing address is 7700 Arlington
Boulevard, Suite 5101, Falls Church, VA 22042-5101. Website: https://health.mil/bap. The most up-to-date changes to the meeting agenda can
be found on the website.
SUPPLEMENTARY INFORMATION: This meeting is being held under the
provisions of the Federal Advisory Committee Act (FACA) of 1972 (5
U.S.C., Appendix, as amended), the Government in the Sunshine Act of
1976 (5 U.S.C. 552b, as amended), and 41 CFR 102-3.140 and 102-3.150.
The Panel will review and comment on recommendations made to the
Director of the Defense Health Agency, by the Pharmacy and Therapeutics
Committee, regarding the Uniform Formulary.
Purpose of the Meeting: The Department of Defense (DoD) is
publishing this notice to announce that the following Federal Advisory
Committee meeting of the Uniform Formulary Beneficiary Advisory Panel
will take place.
Agenda:
1. Sign-In
2. Welcome and Opening Remarks
3. Scheduled Therapeutic Class Reviews (Comments will follow each
agenda item)
a. Migraine Agents--CGRP Prophylaxis Subclass
b. Oncological Agents--Prostate Cancer 2nd Generation Antiandrogen
Subclass
c. Oncological Agents--Prostate Cancer CYP-17 Inhibitors Subclass
4. Newly Approved Drugs Review
5. Pertinent Utilization Management Issues
6. Panel Discussions and Vote
Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and
41 Code of Federal Regulations (CFR) 102-3.140 through 102-3.165, and
the availability of space, this meeting is open to the public. Seating
is limited and will be provided only to the first 220 people signing-
in. All persons must sign-in legibly.
Written Statements: Pursuant to 41 CFR 102-3.140, the public or
interested organizations may submit written statements to the
membership of the Panel about its mission and/or the agenda to be
addressed in this public meeting. Written statements should be
submitted to the Panel's Designated Federal Officer (DFO). The DFO's
contact information can be obtained previously in this announcement.
Written comments or statements must be received by the committee DFO at
least five (5) business days prior to the meeting so that they may be
made available to the Panel for its consideration prior to the meeting.
The DFO will review all submitted written statements and provide copies
to all the committee members.
Dated: February 4, 2019.
Shelly E. Finke,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2019-01437 Filed 2-6-19; 8:45 am]
BILLING CODE 5001-06-P